VJOncology are excited to highlight the latest in immuno-oncology from the 37th Annual Meeting of the Society for Immunotherapy in…

Over 75% of patients with ovarian cancer are diagnosed at an advanced stage, as early-stage disease is usually asymptomatic.1,2 The…

Antibody-drug conjugates (ADCs) are an emerging class of anticancer drugs consisting of a monoclonal antibody linked to a cytotoxic chemotherapy…

Research presented at the European Society of Medical Oncology (ESMO) Congress 2022 has uncovered a non-mutagenic mechanism by which air…

EV-103 (NCT03288545) is a multicohort study investigating the use of the antibody-drug conjugate, enfortumab vedotin, alone or in combination with…

VJOncology are thrilled to present our top picks from the the IASLC 2022 World Conference on Lung Cancer (WCLC) congress!

In the U.S., colorectal cancer (CRC) is the third leading cause of cancer-related deaths and is expected to lead to…

VJOncology are excited to present our top picks from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting!